Arrhythmias & electrophysiologyCohort study
Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies
- Single-arm clinical trial
- prospective
- multicentre
- first-in-human
- 9 centres
Authors' conclusion
In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy.
Study context
- Population
- Patients referred for de novo or second ablation of recurrent monomorphic VT, ischaemic and non-ischaemic aetiologiesage 67 ± 11 years, 78% ischaemic
- Participants
- 64 patients
- Outcome
- Freedom from device- or procedure-related MAEs; acute non-inducibility of clinical VTs at end of procedure; freedom from sustained VT or ICD intervention
- Follow-up
- 30 days (MAEs); end of procedure; 6 months
Main finding
As reported in the abstract
Acute non-inducibility of clinical ventricular tachycardias (VTs) (patients with post-ablation induction attempted)
94% (51/54)
Protocol-defined major adverse events (MAEs) up to 30 days
0
VT-free at 6 months
38 patients (60.3%)
Freedom from defibrillator shock at 6 months
81.0%
Observational data: associations, not effects.
Further findings
VT burden before vs after ablation (patients with ICD ≥6 months before ablation, n = 47)
- Before ablation, median (IQR)
- 4 (1-9)
- After ablation, median (IQR)
- 0 (0-2)
Safety
Procedure-related serious adverse events
- Procedure-related serious adverse events, resolved without clinical sequelae
- 4
- Protocol-defined MAEs
- 0
Original publication
Summarised from the published abstract; every number is checked against it